
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. presents a promising investment opportunity as it trades around $4 per share, with significant upside potential contingent on favorable multi-dose data outcomes. The company has achieved a remarkable 53.7% splicing correction in its therapeutic candidate, PGN-EDO51, which exceeds the performance of competitors, indicating robust efficacy in the treatment of neuromuscular diseases. The Enhanced Delivery Oligonucleotide platform, coupled with a diversified pipeline that includes PGN-EDODM1 and others, positions PepGen favorably in the biotechnology sector, reflecting its potential for substantial advancements in muscle performance with ongoing clinical trials.
Bears say
PepGen Inc.'s stock outlook is negatively affected by a $1 decrease in its target price to $8 per share, reflecting a concerning valuation despite best-in-class data and a favorable safety profile for its DM1 treatment. The company faces heightened risks related to its commercial execution and the potential inability to meet or exceed market expectations, which could adversely impact share performance. Additionally, challenges in accessing capital markets pose significant threats, potentially leading to delays or termination of crucial development programs.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares